Dr. John Cush RheumNow
3 years 11 months ago
8 pts w/ Refractory Skin Dermatomyositis Rx w/ open label APREMILAST, @ 3 mos 7/8 pts responded w/ drop in CDASI (-12.9 pts; P < .001). Skin Bx showed downregulation of multiple inflamm pathways (STAT1/3, IL-4), IL-6, IL-12, IL-23, IFNγ & TNFα) https://t.co/mLElrRgFF1 https://t.co/4eidnPYdXJ
Dr. John Cush RheumNow
3 years 11 months ago
Transitioning JIA to Adult Care is Problematic
Juvenile idiopathic arthritis (JIA) may start in adolescence and extend into adulthood.
This report shows that rheums need to develop "transition" practices to avoid a gap in healthcare.
https://t.co/DV8BZjcP5e https://t.co/e1rFXWSmXN
Dr. John Cush RheumNow
3 years 11 months ago
Rheumatoid Arthritis Patients Need to Quit Smoking ASAP
A report from an early arthritis registry shows that current smoking increases disease activity and lowers health-related quality of life.
https://t.co/04WeK1OlRw https://t.co/yjZQdsrKsH
Dr. John Cush RheumNow
3 years 11 months ago
The University Of Pennsylvania has recv a $50 Million Gift (from Stewart & Judy Colton) to further develop the Autoimmune Disease Research program at Penn’s Colton Center for Autoimmunity. 6.4% of women and 2.7% of men have autoimmune disease https://t.co/7kdTiZnmiD https://t.co/5yXZTzmRM0
Dr. John Cush RheumNow
3 years 11 months ago
Causes of Death in Lupus
The California Lupus Surveillance Project has longitudinally followed included SLE cases and shown that overall, the leading cause of death was CVD, followed by rheumatic disease and hematologic/oncologic conditions.
https://t.co/XRtD2Rr77j https://t.co/fzVGSeQGQu
Dr. John Cush RheumNow
3 years 11 months ago
2 open-label reports of JAK inhibitors in Systemic sclerosis (SSc) - 59 SSc pts: significant decr in mRSS in 88%. 28/29 w/ ILD had no progression. Overall responses better in treatment naïve SSc patients. 20% had side-effects. More studies needed https://t.co/sR2OMNtxAk https://t.co/qOdMEZheFz
Dr. John Cush RheumNow
3 years 11 months ago
Dr. Jack Cush goes off on "Untitling" (not using proper names/titles) in the clinic, in addition to reports on rheumatologist salaries, new drugs in phase 1-3 development and the range of COVID-19 MSK symptoms -- all from the past week on RheumNow.
https://t.co/eHKx2D0kKp https://t.co/UdC0k3hlmX
Dr. John Cush RheumNow
3 years 11 months ago
20% of SLE pregnancies end w/ adverse preg outcome (APO). Use of LASSO & Machine learning of PROMISSE data (385 pt) before wk 12 could predict APO based on BP Meds, low Plts, Dz activity, and LAC (AUC=0.78) https://t.co/DZJ9UCpwCk https://t.co/5yYgj9g0dP
Dr. John Cush RheumNow
3 years 11 months ago
Physician Burnout Rising
The NY Times has reported results of a study showing that nearly 2/3 of doctors are experiencing at least one symptom of burnout, with a marked increase since the onset of the pandemic.
https://t.co/EGDezgyQ9e https://t.co/TmG01Un191
Dr. John Cush RheumNow
3 years 11 months ago
Rheumatology Salaries and Career Choices
A recent doximity report shows how rheumatology salaries increase by years in practice.
https://t.co/Fmzq5zv3yp https://t.co/5Ju7ABiK2m
Dr. John Cush RheumNow
3 years 11 months ago
Opioid Crisis Costs USA $1.5 Trillion
Reuters has reported the results of a Congressional report showing the economic toll of the opioid addiction and overdose crisis on the United States reached nearly $1.5 trillion in 2020 alone and is likely to grow.
https://t.co/n2FC75hpDt https://t.co/UHTOMUDP5Q
Dr. John Cush RheumNow
3 years 11 months ago
Tofacitinib in 15 pts w/ early diffuse skin Scleroderma. Tofa downregulated STAT3 (macrophages, DCs) & IFN (fibroblasts) & MYOC/CCL19 (adventitial fibroblasts); well tolerated & trend to improved mRSS scores (ns) https://t.co/Vt25ui8GwF https://t.co/chKZt6dvaO
Systemic sclerosis is one of the rarest autoimmune diseases, affecting roughly 100,000 people (primarily women) in the U.S. With no licensed treatments available for this subset of scleroderma patients, rheumatology researchers are searching for opportunities to use resources and technology that have proven beneficial in treating other autoimmune and rheumatic diseases.
Dr. Jack Cush goes off on "Untitling" (not using proper names/titles) in the clinic, in addition to reports on rheumatologist salaries, new drugs in phase 1-3 development and the range of COVID-19 MSK symptoms -- all from the past week on RheumNow.com.
